logo-loader

Scancell Holdings close to securing further patent protection over the IP underpinning its Moditope platform

Published: 02:59 20 Nov 2019 EST

Scancell Holdings PLC -

Scancell Holdings PLC (LON:SCLP) said it is close securing to further protection for its technology from the European Patent Office.

The patent will cover the firm’s modified enolase peptides and adds a further layer of legal security over its pipeline of Moditope vaccines for the treatment of cancer.

"The utility of the Moditope technology is increasingly being recognised as a novel and important immuno-therapeutic approach in the treatment of cancer, as evidenced by the expansion of our patent portfolio and selection for presentation on the international stage," chief executive Cliff Holloway said.

In the same announcement investors were told chief scientific officer, Professor Lindy Durrant, has been invited to make a presentation on the discovery of the Moditope and its potential use in patients with solid tumours.

She will be attending the NeoAg Summit in Boston on Friday 22 November.

Scancell CEO hails "exciting" high response rate to melanoma treatment

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) chief executive Professor Lindy Durrant speaks to Thomas Warner from Proactive to provide an update on the initial phase of the clinical stage biopharmaceutical company's Phase 2 SCOPE trial in advanced melanoma. Professor Durrant gives an overview...

on 09/19/2023